Trinity Biotech PLC (TRIB) - NASDAQ
  • Oct. 22, 2015, 12:47 PM
    | Oct. 22, 2015, 12:47 PM | 1 Comment
  • Apr. 2, 2015, 12:45 PM
    | Apr. 2, 2015, 12:45 PM | 2 Comments
  • Jul. 30, 2013, 11:17 AM
    • Trinity Biotech (TRIB -3.1%) Q2: Diluted EPS (ex-Medical Devise Excise Tax) of $0.176.
    • Revenue of $21.3M (+2.4% Y/Y) misses by $0.7M.
    • The company also says it is acquiring Immco Diagnostics for $32.75M, a deal TRIB says will be "immediately earnings accretive." (PR)
    | Jul. 30, 2013, 11:17 AM
  • Jul. 17, 2013, 1:46 PM

    Shares of Trinity Biotech (TRIB +4.6%) get a lift from an upbeat article in Barron's online today, saying that with its diabetes testing equipment gaining rapid acceptance, the stock could gain 40% over the next 18 months. Since launching its Premier Hb9210 in 2011, the device has seeen strong demand. In 2012, its first full year of sales, the company shipped 202 of the Premier devices. This year, it estimates it will ship around 320, aided by its recent entry into China, a potentially large market for the device, with an estimated 54M undiagnosed diabetics.

    | Jul. 17, 2013, 1:46 PM
Company Description
Trinity Biotech Plc develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market. Its products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the... More
Sector: Healthcare
Industry: Diagnostic Substances
Country: Ireland